University of Ioannina
Εκλεκτικοί αναστολείς πρωτεϊνικών κινασών: σχεδιασμός, σύνθεση και μοριακή μοντελοποίηση νέων, ευρέως τροποποιημένων αναλόγων της Ιματινίβης: εισαγωγή των δομών της Χρωμόνης και της Κουμαρίνης
Abstract
dc:descriptionProtein kinases are enzymes that modify other proteins by phosphorylating them. Protein kinases, the major signal transducers involved in all signaling pathways of the cell, are known to affect cellular processes by enzymatically transferring the ATP terminal phosphate group to the hydroxyl of the side chain of serine, threonine, or tyrosine. Selective inhibition of protein kinases, through the synthesis of these inhibitors, has been established as one of the most promising therapeutic strategies for the treatment of diseases such as cancer. Mutations in protein kinase molecules sometimes lead to the autonomic, uncontrolled, behavior of cancer cells, disrupting the mechanisms that regulate cell division, survival, and apoptosis. Many cancers are caused by such mutations. The drug Glivec or Imatinib from the pharmaceutical company "Novartis", a derivative of phenylaminopyrimidine, is the first selective protein kinase inhibitor, which has been successfully administered for several years for the treatment of Chronic Myeloid Leukemia. In the present Ph.D. dissertation we describe the design, synthesis and characterization of new phenylaminopyrimidine derivatives analogous to the medicinal product Imatinib, with structural changes involving: a) removal of the N-methylpiperazine ring and its replacement by substituted benzene rings, chromone and coumarin structures b) the connection of the pyridine to the 4-position of the pyrimidine ring as well as the replacement of the 3-pyridine ring A by a 3-methoxy-benzene ring, b) the replacement of the -NH-linking group between B and C rings by - NHCH2-, or -NHCO- while there are various combinations of the above categories. Another objective of the present PhD thesis was to provide an improved process for the preparation of the imatinib analogues, overcoming the difficulties of the synthetic process described in patents of the Novartis Company. By our synthetic method the inhibitors were isolated much easier and also obtained in higher yields compared to the Novartis synthetic method. All the 22 new inhibitors described herein were fully characterized by IR, 1H NMR, 13C NMR spectroscopy, as well as by high resolution mass spectrometry. The new compounds provide a platform for further drug development against the therapeutically important receptor family PDGF, and they also provide insight into alternative ways of engineering drugs with altered biological activity.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gogou, Marina
- Γώγου, Μαρίνα
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51525